Performance profile April to June 2024
P. 24 Substance Use - 
% of substance users (under 18 years) for whom treatment has commenced within one week following assessment
% of substance users (over 18 years) for whom treatment has commenced within one calendar month following assessment

P.32 Social Inclusion - 
% of substance users (over 18 years) for whom treatment has commenced within one calendar month following assessment – SI22
% of substance users (under 18 years) for whom treatment has commenced within one week following assessment – SI25

P.48 Social Inclusion
Opioid substitution - Social inclusion continues to operate at similar levels to 2023. The total number of clients in receipt of opioid substitution treatment (outside prisons) as of the end of May was 10,277 and is -4.7% below the expected activity level of 10,784 (SI1) * Data return rate 100%
Needle Exchange - The number of unique individuals attending the Pharmacy Needle Exchange Programme at the end of March 2024 (data quarterly in arrears) was 1,341 which represents a decrease of -10.6% in expected activity (1,500) and -18.6% below the same period last year position of 1,647.(SI46) * Data return rate 100%.

P.9 Health and Wellbeing
No. of smokers who received face to face or telephone intensive cessation support from a cessation counsellor – HWB27
% of smokers on cessation programmes who were quit at four weeks – HWB26

P.10 Tobacco smokers – intensive cessation support - Nationally, 5,909 smokers received intensive cessation support from a cessation counsellor at end of Q1 2024 (this metric is reported quarterly in arrears), which is -5.4% below the target of 6,246 and +8.3% ahead of the same period in 2023 (HWB27).

P.15 No. of initial tobacco sales and / or nicotine inhaling product sales to minors test purchase inspections carried out – HWB29

P.16 No initial tobacco sales and/or nicotine inhaling product sales to minors were completed in Q2. National Environmental Health Service is presently awaiting recruitment of additional resources and formal authorisation under new nicotine inhaling product legislation before enforcement can commence

Data management report June 2024

P.119 Opioid Substitution
Total no. of clients in receipt of opioid agonist treatment (outside prisons)
Average waiting time from referral to assessment for opioid agonist treatment (days)
Average waiting time from opioid agonist assessment to exit from waiting list or treatment commenced (days)
Needle exchange
No of unique individuals attending the Pharmacy Needle Exchange Programme

P.122 Social Inclusion 
Alcohol use - No. of problem alcohol users (over 18 years) for whom treatment has commenced within one calendar month following assessment
% of problem alcohol users (over 18 years) for whom treatment has commenced within one calendar month following assessment
No. of problem alcohol users (under 18 years) for whom treatment has commenced within one week following assessment
% of problem alcohol users (under 18 years) for whom treatment has commenced within one week following assessment

P.221 Non-returns of data

P.108 Tobacco - No. of smokers who received face to face or telephone intensive cessation support from a cessation counsellor.
No. of smokers who are receiving online cessation support services
% of smokers on cessation programmes who were quit at four weeks
P.137 No. of initial tobacco sales and/or nicotine inhaling product sales to minors test purchase inspections carried out
No. of inspections of e-cigarette and refill container manufacturers, importers, distributors and retailers under the E.U. (Manufacture, Presentation and Sale of Tobacco and Related Products) Regulations 2016